Mometasone/formoterol
| Combination of | |
|---|---|
| Mometasone furoate | Corticosteroid |
| Formoterol fumarate | Long-acting β2 adrenoreceptor agonist (LABA) |
| Clinical data | |
| Trade names | Zenhale, Dulera, others |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration | Inhalation (Metered-dose inhaler MDI) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
| (what is this?) (verify) | |
Mometasone/formoterol, sold under the brand name Dulera among others, is a fixed-dose combination medication used in the long-term treatment of asthma. It contains mometasone a steroid and formoterol a long-acting beta agonist. It is only recommended in those for whom an inhaled steroid is not sufficient. It is used by inhalation.
Common side effect include headache and sinusitis. More serious side effects may include thrush, immunosuppression, allergic reactions, and cataracts. Use is not recommended in those less than twelve years of age. It has not been studied during pregnancy or breastfeeding. Mometasone works by decreasing inflammation while formoterol works by relaxing smooth muscle in the airways.
The combination was approved for medical use in the United States in 2010. No generic version is available as of 2019. In 2021, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions. It is on the World Health Organization's List of Essential Medicines.